Sensus Healthcare (NASDAQ:SRTS) Stock Crosses Below 50-Day Moving Average – Time to Sell?

Posted by Brenda Bartman on Jun 7th, 2026

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.74 and traded as low as $2.66. Sensus Healthcare shares last traded at $2.70, with a volume of 53,292 shares.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SRTS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Maxim Group cut their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Alliance Global Partners began coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Sensus Healthcare has an average rating of “Moderate Buy” and a consensus price target of $6.88.

View Our Latest Analysis on SRTS

Sensus Healthcare Price Performance

The stock has a market capitalization of $44.44 million, a PE ratio of -5.74 and a beta of 1.09. The business’s fifty day moving average price is $3.74 and its two-hundred day moving average price is $4.09.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pacific Ridge Capital Partners LLC lifted its position in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the period. Divisadero Street Capital Management LP lifted its position in Sensus Healthcare by 39.5% during the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after purchasing an additional 128,224 shares during the period. Geode Capital Management LLC lifted its position in Sensus Healthcare by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after purchasing an additional 5,316 shares during the period. Sachetta LLC lifted its position in Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares during the period. Finally, Greenline Wealth Management LLC acquired a new position in Sensus Healthcare during the fourth quarter valued at $513,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

(Get Free Report)

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.